Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Phase 1 Completed
32 enrolled 15 charts
AML
Phase 1 Completed
10 enrolled
Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma
Phase 2 Completed
33 enrolled
Flavopiridol in Treating Patients With Metastatic Malignant Melanoma
Phase 2 Completed
17 enrolled
Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Phase 2 Completed
18 enrolled
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
78 enrolled 10 charts
Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
Phase 1/2 Completed
28 enrolled 10 charts
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
172 enrolled 12 charts
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Phase 1/2 Completed
52 enrolled 10 charts
Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Phase 2 Completed
36 enrolled 7 charts
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
45 enrolled 7 charts
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Completed
92 enrolled 10 charts
Flavopiridol in Treating Patients With Refractory Cancer
Phase 1 Completed
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1 Completed
39 enrolled
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase 1 Completed
93 enrolled
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
Phase 2 Completed
10 enrolled 9 charts
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
Phase 2 Completed
19 enrolled 8 charts
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Phase 2 Completed
45 enrolled 8 charts
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
13 enrolled
Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
60 enrolled
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
46 enrolled
Combination Chemotherapy in Treating Patients With Advanced Cancer
Phase 1 Completed
90 enrolled
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia
Phase 1/2 Completed
53 enrolled
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
Phase 1 Completed
35 enrolled
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Phase 1 Completed
30 enrolled
Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors
Phase 1 Completed
58 enrolled
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors
Phase 1 Completed
73 enrolled
Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel
Phase 2 Completed
Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase 2 Completed
Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase 2 Completed
Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer
Phase 2 Completed
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Phase 1/2 Completed
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
Phase 1 Completed
37 enrolled
Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
Phase 1 Completed
24 enrolled
Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
Phase 1 Completed
36 enrolled
Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
58 enrolled
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)
Phase 2 Completed
165 enrolled
Flavopiridol in Treating Patients With Recurrent Prostate Cancer
Phase 2 Completed
40 enrolled
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
Phase 2 Completed
40 enrolled
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
24 enrolled
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia
Phase 2 Completed
37 enrolled
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
48 enrolled
Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors
Phase 1 Completed